Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment is a phase 2, interventional study registered as NCT07405476 by Emory University, with a registry enrolment figure of 38 participants, started 2026-04-07 and due to reach its primary completion in 2028-12-18. Interventions recorded: Zanidatamab; Resection; Patient Observation; Echocardiography Test; Multigated Acquisition Scan; Endoscopic Procedure; Computed Tomography; Magnetic Resonance Imaging; Biospecimen Collection; Biopsy Procedure; Digital Rectal Examination; Electronic Health Record Review. Conditions listed: Colon Carcinoma; Colorectal Carcinoma; Rectal Carcinoma; Stage I Colon Cancer AJCC v8; Stage I Colorectal Cancer AJCC v8; Stage I Rectal Cancer AJCC v8; Stage II Colon Cancer AJCC v8; Stage II Colorectal Cancer AJCC v8; Stage II Rectal Cancer AJCC v8; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8. Primary outcome: Rate of Complete and Major Pathologic Regression (Cohort 1); Radiologic Response (Cohort 2); Tumor Regression Grades (Cohort 2). Colorectal eligibility wording from the registry: "* Histologically or cytologically confirmed colon and/or rectal cancer planned for curative intent treatment at gastrointestinal clinics of Emory University's Winship Cancer Institute and collaborating centers". Sites: United States. No results are recorded here; the registry entry is the source.